Montreal, Quebec – January 12, 2017 – Prevtec Microbia Inc. is pleased to announce that its German subsidiary, Prevtec Microbia GmbH, received the market authorization from the European Commission for Coliprotec® F4/F18 in the European Union. Coliprotec® F4/F18 is the first single dose oral vaccine intended for active immunization of pigs against enterotoxigenic F4- and F18-positive Escherichia coli, the two most important agents of post-weaning…
About Prevtec Microbia
Estimated value of the global animal health industry by 2020*
Number of countries where Coliprotec® F4 is approved for use
We have been devising innovative solutions to challenges in livestock production for over a decade.
Prevtec Microbia is pleased to announce that the scientific paper on the efficacy of the Coliprotec® F4 vaccine is now published in the journal Vaccine. Immunogenicity and protective efficacy of a single-dose live non-pathogenic Escherichia coli oral vaccine against F4-positive enterotoxigenic Escherichia coli challenge in pigs
Antimicrobial resistance (AMR) is resistance of a microorganism to an antimicrobial medicine to which it was originally sensitive. AMR occurs naturally but the phenomenon is hugely increased by excessive and inappropriate use of antimicrobial medicines and poor infection control practices in animals and humans.
Source: European Commission, http://europa.eu/rapid/press-release_STATEMENT-15-6097_en.htm
25 000 patients die annually in the EU alone as a result of infections caused by resistant bacteria. Globally this number could be as high as 700 000.
Source: European Commission, http://ec.europa.eu/dgs/health_food-safety/docs/amr_factsheet.pdf